A5033040041- Lymphoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Cancer therapeutics and mechanisms
- CNS Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer-related cognitive impairment studies
- Gastric Cancer Management and Outcomes
- Lysosomal Storage Disorders Research
- Cytomegalovirus and herpesvirus research
- Urinary Tract Infections Management
- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Colorectal Cancer Treatments and Studies
- Polyomavirus and related diseases
First Pavlov State Medical University of St. Petersburg
2019-2024
Anaplastic large cell lymphoma (ALCL) expressing the anaplastic kinase (ALK) (ALK + ALCL) is a rare type of which comprises 10-15% all non-Hodgkin lymphomas in children and 2–3% young adults. Relapsed/refractory disease occurs even more rarely (25–40% cases). There as yet no standard treatment for relapsed/refractory ALK ALCL. Patients with ALCL usually present at advanced stages extranodal involvement (skin, soft tissues, bones, lungs, liver, spleen bone marrow) B symptoms. ALK-positive...
Introduction. Neuroblastoma (NB) is the most common extracranial pediatric solid tumor. The high-risk group patients are characterized by adverse prognosis and require intensive complex therapy including high-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (auto-HSCT). current study presents a single center experience of HSCT auto-HSCT for NB performed in Raisa Gorbacheva Memorial Research Institute Children Oncology, Hematology Transplantation, First Pavlov State...
Treatment of non-Hodgkin lymphomas (NHL) in children using risk-based chemotherapy protocols is currently effective 80–95% cases, even advanced stages the disease. However, relapsed/refractory forms NHL (which are less common) have an extremely unfavorable course with low survival rates. The addition autologous and allogeneic hematopoietic stem cell transplantation (HSCT) to a comprehensive treatment program for can improve results due antitumor effect drugs conditioning regimen...
Introduction: Immune checkpoints inhibitors therapy had shown significant activity in patients with relapsed or refractory classical Hodgkin lymphoma (r/r cHL). However, disease relapse progression is observed the majority of patients. One potential approach to enhance effect anti-PD1 a combination chemotherapy. Bendamustine bifunctional alkylating agent antimetabolite properties that demonstrated for treatment r/r cHL and therefore may be candidate drug combined regimen. The aim this...
The majority of children with NHL can be cured first-line therapy but 10–25% affected patients develop relapsed or refractory disease (R-R). prognosis in these cases is unfavorable, no matter what form modern treatment adopted. New approaches to the this small, yet important, group need introduced, including, first and foremost, targeted immunotherapy. As known, PD-L1 frequently expressed non-Hodgkin lymphomas (NHL), which means that use checkpoint inhibitors (CPI) theoretically justified....
Результаты аллогенной трансплантации гемопоэтических стволовых клеток с режимом кондиционирования сниженной интенсивности доз у пациентов синдромом Гурлер
Background. Ewing sarcoma (EWS) is a second most common pediatric bone tumor. About one quarter of all patients belong to high-risk group characterized by poor prognosis. In spite high-dose chemotherapy (HDCT) with autologous hemopoietic stem cell transplantation (auto-HSCT) being traditionally viewed as possible option for patients, there stills no consensus on indications this method in EWS patients. Study objective: evaluate the HDCT effectiveness and important prognostic factors...
About 20% of initially high-risk patients with neuroblastoma (NB) develop primary resistant to chemotherapy and more than 50% them subsequently have a relapse. There is currently no uniform approach therapy in this group long-term outcomes are dismal. The study was approved by the Independent Ethics Committee Scientific Council I.P. Pavlov First Saint Petersburg State Medical University. A total 78 median age 5 (1–20) years (n = 33) or 45) relapsed NB receiving treatment R.M. Gorbacheva...
Background: There is no standard therapy for B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large lymphoma and Hodgkin (intermediate DLBCL/HL) because of its recent identification as a distinct entity by WHO rarity described cases. At the same time, patients relapsed refractory disease represent group dismal prognosis. Recent studies revealed that DLBCL/HL has frequent chromosome 9p24.1 alterations hence use PD‐1 blockade might be effective treatment option. To...
Children and adolescents with refractory or relapsed Hodgkin's lymphoma (R-R HL) have unfavorable prognosis if ≥ 3 lines of therapies to be used. New strategies based on innovative approaches are crucial for this group patients. Nowadays immunotherapy oncological diseases is the most promising actively developing area. Brentuximab vedotin (BV) efficient in adults HL. Data children limited pilot studies that focused response treatment without analysis survival. The present study demonstrates...
Introduction. Neuroblastoma (NB) is the most common extracranial solid tumor in infants, but it more rarely found older children. Only 1–2 % of cases are registered adolescents and young adults. The long-term prognosis these patients highly unfavorable due to indolent clinical course formed by peculiar biological characteristics tumors. We publish a case study 11 with NB than 10 years at time diagnosis. Case series description. In 2008 2020 total adolescent adults median age 14 (10–28) were...
Introduction. The long-term event-free survival of patients with high-risk neuroblastoma (NB) receiving intensive complex therapy according to current russian standard do not exceed 40 %. Also, there is no tactics in primary resistant and relapsed disease, most them die due disease progression. While, anti-GD2 immunotherapy (IT) proved be effective NB, Russian Federation this method generally available. There are currently two pilot studies ongoing Raisa Gorbacheva Memorial Institute aimed...
Abstract Introduction The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. present study aimed assess the results of PTCy‐based GVHD prophylaxis a large cohort children with allo‐HSCT. Methods A retrospective analysis 190 patients who had first allograft between 2008 and 2020 from sibling donor (MSD) or unrelated (MUD) was carried out. In MSD setting, consisted PTCy alone ( n = 28) for group, calcineurin inhibitor...
Presence of bacteriuria and urinary microbiota composition is an important index immunocompromised conditions. These parameters are scarcely studied in patients undergoing hematopoietic stem cell transplantation (HSCT). The aim this work was to evaluate detection rates cultured aerobic from urine samples taken by clinical indications before HSCT within 4 months after the treatment. study approved Independent Ethics Committee Scientific Council I.P. Pavlov First Saint Petersburg State Medical...
High-dose chemotherapy (HDCT) with autologous hemopoietic stem cell transplantation (auto-HSCT) is currently an integral part of a standard care for younger medulloblastoma (MB) patients and MB relapse. As HDCT regimens are characterized by neurotoxicity, it may add to the one radiation therapy. Therefore, some develop post-irradiation clinical symptoms MRI changes characteristic disease progression, pseudoprogression. We report on case 16-year old patient relapsed treated consequent...
The majority of patients with Hodgkin lymphoma (HL) are cured, which represents one the best cure rates in oncology. However, prognosis is not as favorable case relapsed or refractory (RR) disease. Autologous hematopoietic stem cell transplantation (auto-HSCT) an effective way to consolidate remission RR HL. Despite many years experience and availability results randomized trials confirming efficacy high-dose chemotherapy adults, role auto-HSCT children HL has been studied extensively, there...
Lymphoblastic lymphoma (LBL) in children is curable most cases, but there still a significant proportion of patients whom standard therapy ineffective. Thus, develop relapse or primary refractory disease about 10% cases (R/R). In this case, the main treatment method allogeneic hematopoietic stem cell transplantation (allo-HSCT). The choice favor predominantly based on experience adult patients. A small number pediatric accounts for limited data pediatrics. prognosis these always extremely...
There is no doubt that autologous hematopoietic stem cell transplantation (auto-HSCT) with high-dose polychemotherapy (PCT) a standard method for the second remission consolidation in case of relapse or fist refractory disease adult patients non-Hodgkin lymphomas (NHL) (with exception lymphoblastic lymphoma which allogeneic preferable). Similar to older than 18 years age, an identical algorithm applied pediatric patients, however absence randomized clinical trials and due small number...